Pub Date : 2022-04-21DOI: 10.1136/heartjnl-2022-BCS-foreword
{"title":"Foreword: Her Royal Highness The Princess Royal","authors":"","doi":"10.1136/heartjnl-2022-BCS-foreword","DOIUrl":"https://doi.org/10.1136/heartjnl-2022-BCS-foreword","url":null,"abstract":"","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"747 - 747"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41996272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-21DOI: 10.1136/heartjnl-2021-320142
F. Dunn, A. R. Lorimer
{"title":"The Scottish contribution: the importance of the National Cardiac Societies and the Royal Colleges and their 100-year association with BCS","authors":"F. Dunn, A. R. Lorimer","doi":"10.1136/heartjnl-2021-320142","DOIUrl":"https://doi.org/10.1136/heartjnl-2021-320142","url":null,"abstract":"","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"753 - 754"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41998304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-21DOI: 10.1136/heartjnl-2021-320145
W. Moody, P. Elliott
Sixty years ago, hypertrophic cardiomyopathy (HCM) was considered a rare lethal disease that affected predominantly young adults and for which there were few treatment options. Today, it is recognised to be a relatively common disorder that presents throughout the life course with a heterogeneous clinical phenotype that can be managed effectively in the majority of individuals. A greater awareness of the condition and less reluctance from healthcare practitioners to make the diagnosis, coupled with improvements in cardiac imaging, including greater use of artificial intelligence and improved yields from screening efforts, have all helped facilitate a more precise and timely diagnosis. This enhanced ability to diagnose HCM early is being paired with innovations in treatment, which means that the majority of patients receiving a contemporary diagnosis of HCM can anticipate a normal life expectancy and expect to maintain a good functional status and quality of life. Indeed, with increasing translation of molecular genetics from bench to bedside associated with a growing number of randomised clinical trials of novel therapies aimed at ameliorating or perhaps even preventing the disease, the next chapter in the story for HCM will provide much excitement and more importantly, offer much anticipated reward for our patients.
{"title":"Changing concepts in heart muscle disease: the evolving understanding of hypertrophic cardiomyopathy","authors":"W. Moody, P. Elliott","doi":"10.1136/heartjnl-2021-320145","DOIUrl":"https://doi.org/10.1136/heartjnl-2021-320145","url":null,"abstract":"Sixty years ago, hypertrophic cardiomyopathy (HCM) was considered a rare lethal disease that affected predominantly young adults and for which there were few treatment options. Today, it is recognised to be a relatively common disorder that presents throughout the life course with a heterogeneous clinical phenotype that can be managed effectively in the majority of individuals. A greater awareness of the condition and less reluctance from healthcare practitioners to make the diagnosis, coupled with improvements in cardiac imaging, including greater use of artificial intelligence and improved yields from screening efforts, have all helped facilitate a more precise and timely diagnosis. This enhanced ability to diagnose HCM early is being paired with innovations in treatment, which means that the majority of patients receiving a contemporary diagnosis of HCM can anticipate a normal life expectancy and expect to maintain a good functional status and quality of life. Indeed, with increasing translation of molecular genetics from bench to bedside associated with a growing number of randomised clinical trials of novel therapies aimed at ameliorating or perhaps even preventing the disease, the next chapter in the story for HCM will provide much excitement and more importantly, offer much anticipated reward for our patients.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"768 - 773"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46342188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-21DOI: 10.1136/heartjnl-2021-320150
R. Al-Lamee, Louise Aubiniere-Robb, C. Berry
In this article, we provide a historical view of key aspects of British Cardiovascular Society (BCS) influence in clinical trials of ischaemic heart disease (IHD) followed by key research and developments, notable publications and future perspectives. We discuss the role of the BCS and its members. The scope of this article covers clinical trials in stable IHD and acute coronary syndromes, including interventions relating to diagnosis, treatment and management. We discuss the role of the BCS in supporting the original RITA trials. We highlight the changing face of angina and its management providing contemporary and future insights into microvascular disease, ischaemic symptoms with no obstructive coronary arteries and, relatedly, myocardial infarction with no obstructive coronary arteries. The article is presented as a brief overview of the BCS in IHD research, relationships with stakeholders, patient and public involvement and clinical trials from the perspective of past, present and future possibilities.
{"title":"The British Cardiovascular Society and clinical studies in ischaemic heart disease: from RITA to ORBITA, and beyond","authors":"R. Al-Lamee, Louise Aubiniere-Robb, C. Berry","doi":"10.1136/heartjnl-2021-320150","DOIUrl":"https://doi.org/10.1136/heartjnl-2021-320150","url":null,"abstract":"In this article, we provide a historical view of key aspects of British Cardiovascular Society (BCS) influence in clinical trials of ischaemic heart disease (IHD) followed by key research and developments, notable publications and future perspectives. We discuss the role of the BCS and its members. The scope of this article covers clinical trials in stable IHD and acute coronary syndromes, including interventions relating to diagnosis, treatment and management. We discuss the role of the BCS in supporting the original RITA trials. We highlight the changing face of angina and its management providing contemporary and future insights into microvascular disease, ischaemic symptoms with no obstructive coronary arteries and, relatedly, myocardial infarction with no obstructive coronary arteries. The article is presented as a brief overview of the BCS in IHD research, relationships with stakeholders, patient and public involvement and clinical trials from the perspective of past, present and future possibilities.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"800 - 806"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45341448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-21DOI: 10.1136/heartjnl-2021-320139
C. Coats
In 2022, the British Cardiovascular Society celebrates the centenary of its foundation. Starting out as a small group of government-appointed physicians interested in heart disease, the Cardiac Club has grown and adapted to represent all those working in cardiovascular care and research. The historical stages of the organisation’s development are outlined, alongside major innovations in science and technology providing context for a rapidly changing medical world. Only a small part of the history of cardiology in Britain is told, with greater emphasis on describing the broader need for services, skilled workforce, healthcare policy and continuing education. Above all, the history of the British Cardiovascular Society is a story of people and places. The people are those with vision, attitude and leadership to improve the care of communities across the world. The places are those that enabled conversation, innovation and freedom to bring about change. It is hard to believe the remarkable progress in diagnosis, prevention and treatment of heart disease over 100 years, but a thriving modern Society must be the greatest legacy of its founders.
{"title":"History of the British Cardiovascular Society","authors":"C. Coats","doi":"10.1136/heartjnl-2021-320139","DOIUrl":"https://doi.org/10.1136/heartjnl-2021-320139","url":null,"abstract":"In 2022, the British Cardiovascular Society celebrates the centenary of its foundation. Starting out as a small group of government-appointed physicians interested in heart disease, the Cardiac Club has grown and adapted to represent all those working in cardiovascular care and research. The historical stages of the organisation’s development are outlined, alongside major innovations in science and technology providing context for a rapidly changing medical world. Only a small part of the history of cardiology in Britain is told, with greater emphasis on describing the broader need for services, skilled workforce, healthcare policy and continuing education. Above all, the history of the British Cardiovascular Society is a story of people and places. The people are those with vision, attitude and leadership to improve the care of communities across the world. The places are those that enabled conversation, innovation and freedom to bring about change. It is hard to believe the remarkable progress in diagnosis, prevention and treatment of heart disease over 100 years, but a thriving modern Society must be the greatest legacy of its founders.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"761 - 766"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44141726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-21DOI: 10.1136/heartjnl-2021-320146
L. Dobson, B. Prendergast
In the centenary year of the British Cardiovascular Society (BCS), this review article outlines the influence of UK cardiologists and surgeons on the field of heart valve disease, many of whom can rightly claim ‘world firsts’ in the field. From the description of endocarditis as we know it today at the turn of the 20th century, to the first mitral valvotomy, heart valve replacement and invention of the Ross procedure. These advances have transformed the outlook of patients with symptomatic valve disease from palliation and certain death to curative treatment and near normal life expectancy. Transcatheter aortic valve implantation (TAVI) was adopted early in the UK, and thanks to the comprehensive national database, the UK TAVI registry is one of the world’s largest, contributing real-world patient data to inform clinical practice. The more recent concepts of ‘Heart Valve Centres of Excellence’ and specialist valve clinics have been developed by the BCS-affiliated British Heart Valve Society which continues to drive improved standards for patients with heart valve disease. The next 100 years will no doubt be equally thrilling in terms of innovation for heart valve disease, with artificial intelligence, transcatheter therapies and cutting-edge technology continuing to improve patient care and clinical outcomes.
{"title":"Heart valve disease: a journey of discovery","authors":"L. Dobson, B. Prendergast","doi":"10.1136/heartjnl-2021-320146","DOIUrl":"https://doi.org/10.1136/heartjnl-2021-320146","url":null,"abstract":"In the centenary year of the British Cardiovascular Society (BCS), this review article outlines the influence of UK cardiologists and surgeons on the field of heart valve disease, many of whom can rightly claim ‘world firsts’ in the field. From the description of endocarditis as we know it today at the turn of the 20th century, to the first mitral valvotomy, heart valve replacement and invention of the Ross procedure. These advances have transformed the outlook of patients with symptomatic valve disease from palliation and certain death to curative treatment and near normal life expectancy. Transcatheter aortic valve implantation (TAVI) was adopted early in the UK, and thanks to the comprehensive national database, the UK TAVI registry is one of the world’s largest, contributing real-world patient data to inform clinical practice. The more recent concepts of ‘Heart Valve Centres of Excellence’ and specialist valve clinics have been developed by the BCS-affiliated British Heart Valve Society which continues to drive improved standards for patients with heart valve disease. The next 100 years will no doubt be equally thrilling in terms of innovation for heart valve disease, with artificial intelligence, transcatheter therapies and cutting-edge technology continuing to improve patient care and clinical outcomes.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"774 - 779"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42333143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-13DOI: 10.1136/heartjnl-2022-320992
M. Saji, M. Nanasato
long- consequence of mediated, multisystem following a group A strepto-coccal by leaflet commissural The
长期介导的后果，多系统跟随a组链球菌由小叶连接
{"title":"Transcatheter aortic valve replacement: a gatekeeper for improving global disparities in patients with severe aortic stenosis","authors":"M. Saji, M. Nanasato","doi":"10.1136/heartjnl-2022-320992","DOIUrl":"https://doi.org/10.1136/heartjnl-2022-320992","url":null,"abstract":"long- consequence of mediated, multisystem following a group A strepto-coccal by leaflet commissural The","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"1169 - 1170"},"PeriodicalIF":0.0,"publicationDate":"2022-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41860301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-13DOI: 10.1136/heartjnl-2021-320684
S. Marschner, A. von Huben, S. Zaman, H. Reynolds, V. W. Lee, P. Choudhary, L. Mehta, C. Chow
Objective This study aims to examine the incidence of pregnancy-related cardiometabolic conditions and severe cardiovascular outcomes, and their relationship in US Medicaid-funded women. Methods Medicaid is a government-sponsored health insurance programme for low-income families in the USA. We report the incidence of pregnancy-related cardiometabolic conditions (hypertensive disorders and diabetes in, or complicated by, pregnancy) and severe cardiovascular outcomes (myocardial infarction, stroke, acute heart failure, cardiomyopathy, cardiac arrest, ventricular fibrillation, ventricular tachycardia, aortic dissection/aneurysm and peripheral vascular disease) among Medicaid-funded women with a birth (International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code O80 or O82) over the period January 2015–June 2019, from the states of Georgia, Ohio and Indiana. In this cross-sectional cohort, we examined the relationship between pregnancy-related cardiometabolic conditions and severe cardiovascular outcomes from pregnancy through to 60 days after birth using multivariable models. Results Among 74 510 women, mean age 26.4 years (SD 5.5), the incidence per 1000 births of pregnancy-related cardiometabolic conditions was 224.3 (95% CI 221.3 to 227.3). The incidence per 1000 births of severe cardiovascular conditions was 10.8 (95% CI 10.1 to 11.6). Women with pregnancy-related cardiometabolic conditions were at greater risk of having a severe cardiovascular condition with an age-adjusted OR of 3.1 (95% CI 2.7 to 3.5). Conclusion This US cohort of Medicaid-funded women have a high incidence of severe cardiovascular conditions during pregnancy. Cardiometabolic conditions of pregnancy conferred threefold higher odds of severe cardiovascular outcomes.
目的本研究旨在探讨美国医疗补助妇女妊娠相关心脏代谢疾病和严重心血管结局的发生率及其关系。方法医疗补助是美国政府资助的一项针对低收入家庭的医疗保险计划。我们报告了在接受医疗补助的分娩妇女中与妊娠相关的心脏代谢疾病(妊娠期高血压疾病和糖尿病或妊娠并发症)和严重心血管结局(心肌梗死、中风、急性心力衰竭、心肌病、心脏骤停、心室颤动、室性心动过速、主动脉夹层/动脉瘤和外周血管疾病)的发生率(《国际疾病分类》第十版)。2015年1月至2019年6月期间的临床修改(ICD-10-CM)诊断代码O80或O82，来自乔治亚州、俄亥俄州和印第安纳州。在这个横断面队列中，我们使用多变量模型检查了妊娠相关的心脏代谢状况与妊娠至出生后60天严重心血管结局之间的关系。结果在74510名女性中，平均年龄26.4岁(SD 5.5)，每1000个新生儿中与妊娠相关的心脏代谢疾病的发生率为224.3 (95% CI 221.3至227.3)。每1000个新生儿中严重心血管疾病的发生率为10.8 (95% CI 10.1 - 11.6)。患有妊娠相关心脏代谢疾病的妇女患严重心血管疾病的风险更高，经年龄调整的OR为3.1 (95% CI为2.7至3.5)。结论:美国医疗补助女性在怀孕期间严重心血管疾病的发生率很高。妊娠期间的心脏代谢状况使发生严重心血管疾病的几率增加了三倍。
{"title":"Pregnancy-related cardiovascular conditions and outcomes in a United States Medicaid population","authors":"S. Marschner, A. von Huben, S. Zaman, H. Reynolds, V. W. Lee, P. Choudhary, L. Mehta, C. Chow","doi":"10.1136/heartjnl-2021-320684","DOIUrl":"https://doi.org/10.1136/heartjnl-2021-320684","url":null,"abstract":"Objective This study aims to examine the incidence of pregnancy-related cardiometabolic conditions and severe cardiovascular outcomes, and their relationship in US Medicaid-funded women. Methods Medicaid is a government-sponsored health insurance programme for low-income families in the USA. We report the incidence of pregnancy-related cardiometabolic conditions (hypertensive disorders and diabetes in, or complicated by, pregnancy) and severe cardiovascular outcomes (myocardial infarction, stroke, acute heart failure, cardiomyopathy, cardiac arrest, ventricular fibrillation, ventricular tachycardia, aortic dissection/aneurysm and peripheral vascular disease) among Medicaid-funded women with a birth (International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code O80 or O82) over the period January 2015–June 2019, from the states of Georgia, Ohio and Indiana. In this cross-sectional cohort, we examined the relationship between pregnancy-related cardiometabolic conditions and severe cardiovascular outcomes from pregnancy through to 60 days after birth using multivariable models. Results Among 74 510 women, mean age 26.4 years (SD 5.5), the incidence per 1000 births of pregnancy-related cardiometabolic conditions was 224.3 (95% CI 221.3 to 227.3). The incidence per 1000 births of severe cardiovascular conditions was 10.8 (95% CI 10.1 to 11.6). Women with pregnancy-related cardiometabolic conditions were at greater risk of having a severe cardiovascular condition with an age-adjusted OR of 3.1 (95% CI 2.7 to 3.5). Conclusion This US cohort of Medicaid-funded women have a high incidence of severe cardiovascular conditions during pregnancy. Cardiometabolic conditions of pregnancy conferred threefold higher odds of severe cardiovascular outcomes.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"1524 - 1529"},"PeriodicalIF":0.0,"publicationDate":"2022-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47124949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-12DOI: 10.1136/heartjnl-2022-320974
M. McDermott, R. Bing
A clinical diagnosis of suspected angina that is accompanied by non- obstructive epicardial coronary artery disease is not uncommon, as evidenced by results from contemporary registries and trials of anatomical testing in chest pain. The basket labelled as angina with non-obstructive coronary artery disease (ANOCA—the clinical syndrome that may or may not accompany ischaemia with non- obstructive coronary artery disease (INOCA)) contains heterogeneous patho-physiological entities which vary in clinical presentation and adjunctive investigation findings. 1 One distinct entry in this field is vasospastic angina, a dynamic phenomenon with characteristic symptoms that differ from those induced by fixed epicardial coronary artery stenoses. Although the seminal case series which provided the eponymous nomen-clature for this clinical syndrome was published well before many (probably most) readers of Heart were born, attempts to codify and standardise defini-tions for vasospastic angina have only recently been promulgated. 2 The syndrome is seen in only a small propor-tion of patients with chest pain, with correspondingly limited sections in current guidelines. 3 4 The diagnostic process can be difficult and the clinical course uncertain. The latter is salient, events. 5
{"title":"Coronary vasospasm and future percutaneous coronary intervention: relax","authors":"M. McDermott, R. Bing","doi":"10.1136/heartjnl-2022-320974","DOIUrl":"https://doi.org/10.1136/heartjnl-2022-320974","url":null,"abstract":"A clinical diagnosis of suspected angina that is accompanied by non- obstructive epicardial coronary artery disease is not uncommon, as evidenced by results from contemporary registries and trials of anatomical testing in chest pain. The basket labelled as angina with non-obstructive coronary artery disease (ANOCA—the clinical syndrome that may or may not accompany ischaemia with non- obstructive coronary artery disease (INOCA)) contains heterogeneous patho-physiological entities which vary in clinical presentation and adjunctive investigation findings. 1 One distinct entry in this field is vasospastic angina, a dynamic phenomenon with characteristic symptoms that differ from those induced by fixed epicardial coronary artery stenoses. Although the seminal case series which provided the eponymous nomen-clature for this clinical syndrome was published well before many (probably most) readers of Heart were born, attempts to codify and standardise defini-tions for vasospastic angina have only recently been promulgated. 2 The syndrome is seen in only a small propor-tion of patients with chest pain, with correspondingly limited sections in current guidelines. 3 4 The diagnostic process can be difficult and the clinical course uncertain. The latter is salient, events. 5","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"1253 - 1254"},"PeriodicalIF":0.0,"publicationDate":"2022-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44595615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-11DOI: 10.1136/heartjnl-2022-320909
S. Straw, W. Mullens, K. Witte
Cardiac resynchronisation therapydefibrillators (CRTD) would seem the obvious choice for patients with heart failure with reduced ejection fraction, given implantable cardioverter defibrillators (ICD) reduce the risk of sudden cardiac death in this population. However, despite decades of discussion, COMPANION (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure) remains the only trial to include both CRTD and CRTpacemakers (CRTP) in which outcomes between the two approaches were similar.
{"title":"Cardiac resynchronisation therapy with or without a defibrillator: individualising device prescription","authors":"S. Straw, W. Mullens, K. Witte","doi":"10.1136/heartjnl-2022-320909","DOIUrl":"https://doi.org/10.1136/heartjnl-2022-320909","url":null,"abstract":"Cardiac resynchronisation therapydefibrillators (CRTD) would seem the obvious choice for patients with heart failure with reduced ejection fraction, given implantable cardioverter defibrillators (ICD) reduce the risk of sudden cardiac death in this population. However, despite decades of discussion, COMPANION (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure) remains the only trial to include both CRTD and CRTpacemakers (CRTP) in which outcomes between the two approaches were similar.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"1164 - 1166"},"PeriodicalIF":0.0,"publicationDate":"2022-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44912625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：